RESUMO
Herpes zoster (HZ) occurs at a higher age-specific rate in people living with HIV (PLWH) than in the general population. We implemented a quality improvement study to assess herpes zoster vaccine (HZV) usage among PLWH, assess HZV usage after additional reminders/prompts, and identify barriers to HZV among older PLWH. HZV rates in PLWH were determined in six institutions with varying payment structures. For the intervention, Part 1, PLWH eligible for HZV at the University of Colorado were identified, and providers were notified of patient eligibility. In Part 2, in addition to provider notification, an order for HZV was placed in the patient's chart before a clinic appointment. HZ vaccination rates ranged from 1.5% to 42.4% at six sites. Before the intervention, 21.3% of eligible University of Colorado patients had received HZV. An additional 8.3% received HZV with Part 1 and 17.8% with Part 2 interventions. At completion, a total of 53.2% of eligible patients had received HZV through routine clinical care or the interventions. Insurance coverage concern was cited as a common reason for not receiving HZV. Minor adverse reactions occurred in 26.7% patients and did not require medical care. HZV coverage was low at a majority of sites. Clinical reminders with links to vaccination orders or preplaced vaccination orders led to improved HZV coverage in our clinic, but published guidelines for use of HZV in PLWH and improvement in logistic or insurance barriers to HZV receipt are paramount to improved HZV coverage.
Assuntos
Infecções por HIV/complicações , Vacina contra Herpes Zoster/administração & dosagem , Herpes Zoster/prevenção & controle , Cobertura Vacinal , Idoso , Idoso de 80 Anos ou mais , Colorado , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
ABSTRACT Introduction. Interferon-free, multi-direct acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection is highly effective and well tolerated, but costly. To gain perspective on the evolving economics of HCV therapy, we compared the cost per cure of a multi-DAA regimen with the prior standard of triple therapy. Material and methods. Patients infected with HCV genotype 1 who were treated through the University of Colorado Hepatology Clinic between May 2011 and December 2014 comprised the study population. The multi-DAA regimen of simeprevir plus sofosbuvir (SMV/SOF) was compared to the triple therapy regimen consisting of peginterferon and ribavirin, with either boceprevir or telaprevir (TT). Sustained-virologic response (SVR) rates, total costs per treatment and adverse events were recorded. Total cost per SVR were compared for the two treatments, controlling for patient demographics and clinical characteristics. Results. One hundred eighty-three patients received SMV/SOF (n = 70) or TT (n = 113). Patients receiving SMV/SOF were older, more treatment experienced, and had a higher stage of fibrosis. SVRs were 86% and 59%, average total costs per patient were $152,775 and $95,943, and average total costs per SVR were $178,237 vs. $161,813.49 for SMV/SOF and TT groups, respectively. Medication costs accounted for 98% of SMV/SOF and 85% of TT treatment costs. Conclusion. The high cure rate of multi-DAA treatment of HCV is offset by the high costs of the DAAs, such that the cost per cure from TT to multi-DAA therapy has been relatively constant. In order to cure more patients, either additional financial resources will need to be allocated to the treatment of HCV or drug costs will need to be reduced.
Assuntos
Humanos , Inibidores de Proteases/economia , Inibidores de Proteases/uso terapêutico , Hepacivirus/efeitos dos fármacos , Hepatite C Crônica/economia , Hepatite C Crônica/tratamento farmacológico , Simeprevir/economia , Simeprevir/uso terapêutico , Sofosbuvir/economia , Sofosbuvir/uso terapêutico , Ambulatório Hospitalar/economia , Inibidores de Proteases/efeitos adversos , Indução de Remissão , Colorado , Resultado do Tratamento , Análise Custo-Benefício , Hepacivirus/enzimologia , Hepacivirus/genética , Modelos Econômicos , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/virologia , Quimioterapia Combinada , Simeprevir/efeitos adversos , Sofosbuvir/efeitos adversos , Resposta Viral Sustentada , GenótipoRESUMO
INTRODUCTION: Interferon-free, multi-direct acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection is highly effective and well tolerated, but costly. To gain perspective on the evolving economics of HCV therapy, we compared the cost per cure of a multi-DAA regimen with the prior standard of triple therapy. MATERIAL AND METHODS: Patients infected with HCV genotype 1 who were treated through the University of Colorado Hepatology Clinic between May 2011 and December 2014 comprised the study population. The multi-DAA regimen of simeprevir plus sofosbuvir (SMV/SOF) was compared to the triple therapy regimen consisting of peginterferon and ribavirin, with either boceprevir or telaprevir (TT). Sustained-virologic response (SVR) rates, total costs per treatment and adverse events were recorded. Total cost per SVR were compared for the two treatments, controlling for patient demographics and clinical characteristics. RESULTS: One hundred eighty-three patients received SMV/SOF (n = 70) or TT (n = 113). Patients receiving SMV/SOF were older, more treatment experienced, and had a higher stage of fibrosis. SVRs were 86% and 59%, average total costs per patient were $152,775 and $95,943, and average total costs per SVR were $178,237 vs. $161,813.49 for SMV/SOF and TT groups, respectively. Medication costs accounted for 98% of SMV/SOF and 85% of TT treatment costs. CONCLUSION: The high cure rate of multi-DAA treatment of HCV is offset by the high costs of the DAAs, such that the cost per cure from TT to multi-DAA therapy has been relatively constant. In order to cure more patients, either additional financial resources will need to be allocated to the treatment of HCV or drug costs will need to be reduced.
Assuntos
Antivirais/economia , Antivirais/uso terapêutico , Custos de Medicamentos , Hepacivirus/efeitos dos fármacos , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/economia , Inibidores de Proteases/economia , Inibidores de Proteases/uso terapêutico , Simeprevir/economia , Simeprevir/uso terapêutico , Sofosbuvir/economia , Sofosbuvir/uso terapêutico , Adulto , Idoso , Antivirais/efeitos adversos , Colorado , Análise Custo-Benefício , Quimioterapia Combinada , Feminino , Genótipo , Hepacivirus/enzimologia , Hepacivirus/genética , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/virologia , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Econômicos , Ambulatório Hospitalar/economia , Inibidores de Proteases/efeitos adversos , Indução de Remissão , Simeprevir/efeitos adversos , Sofosbuvir/efeitos adversos , Resposta Viral Sustentada , Resultado do TratamentoRESUMO
AIM: To quantify drug-drug-interactions (DDIs) encountered in patients prescribed hepatitis C virus (HCV) treatment, the interventions made, and the time spent in this process. METHODS: As standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral (DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir (LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir (OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics. RESULTS: Six hundred and sixty four patients (83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients. CONCLUSION: DDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care.
Assuntos
Antivirais/uso terapêutico , Interações Medicamentosas , Hepatite C Crônica/tratamento farmacológico , Analgésicos , Quimioterapia Combinada , Feminino , Hepacivirus/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Farmacêuticos , Farmácia/métodos , Estudos Retrospectivos , Ribavirina/administração & dosagem , Simeprevir/administração & dosagem , Sofosbuvir/administração & dosagem , Resultado do TratamentoRESUMO
Individuals with lower inosine triphosphatase (ITPA) enzyme activity have a reduced likelihood of experiencing hemolytic anemia during hepatitis C virus (HCV) treatment containing ribavirin (RBV). Because ITPA degrades purines and RBV is a purine analogue, it is conceivable that ITPA activity may affect intracellular RBV concentrations. Here we assessed the association between ITPA activity phenotype and concentrations of RBV triphosphate (RBV-TP) in red blood cells (RBCs) during HCV treatment. RBV-TP was quantified in the RBCs of 177 HCV-infected individuals at a median (range) of 84 (19 to 336) days into HCV treatment that included RBV. Mean (SD) RBV-TP concentrations were 92.8 (51.6), 101.3 (53.5), 184.8 (84.5), and 197.7 (64.6) pmol/106 cells for 100%, 60%, 30%, and ≤10% ITPA activity groups, respectively. Overall, RBV-TP was approximately 2-fold higher in patients with ≤30% ITPA activity compared to 100% activity (P < .0001). Despite higher RBV-TP levels, individuals with variant ITPA phenotypes had less anemia. The 100% activity group had, on average, a -2.20 g/dL drop in hemoglobin vs -1.43 g/dL (P = .04) for 60% activity, -1.14 g/dL (P = .008) for 30% activity, and -0.70 g/dL (P = .06) for ≤10% activity. This finding of higher RBV-TP concentrations in RBCs in ITPA variants was unexpected given that ITPA activity-deficient individuals have a reduced likelihood of RBV-induced anemia. It also refutes the hypothesis that the mechanism by which ITPA variants are protected against anemia is due to lower RBV-TP levels in RBCs.
Assuntos
Variantes Farmacogenômicos/fisiologia , Fenótipo , Pirofosfatases/sangue , Pirofosfatases/genética , Ribavirina/sangue , Adulto , Estudos de Coortes , Feminino , Hepatite C Crônica/sangue , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/genética , Humanos , Masculino , Pessoa de Meia-Idade , Ribavirina/uso terapêutico , Inosina TrifosfataseAssuntos
Coinfecção , Hepacivirus , Antivirais , Infecções por HIV , Hepatite C , Hepatite C Crônica , Humanos , RibavirinaRESUMO
BACKGROUND: Despite advances in safety, tolerability, and decreased pill burden for human immunodeficiency virus (HIV) antiretroviral therapy (ART), nonadherence continues to be a major cause of HIV-related morbidity and mortality. Adherence to these medications presents particular challenges because persons living with HIV (PLWH) must use medication more consistently (≥ 95%) than persons with other chronic diseases, such as hypertension or diabetes mellitus (≥ 80%). OBJECTIVES: To (a) quantify PLWH adherence rates to scheduled ART, blood pressure medications, or mental health medications, (b) examine how pill burden and dosing schedule affected adherence, and (c) analyze a non-HIV comparator group for comparison with PLWH patients on adherence rates. METHODS: Patients ≥ 18 years of age, on any prescribed HIV ART, scheduled prescription blood pressure medication, or scheduled prescription mental health medication filled between March 1, 2012, and March 31, 2013, were included in the analysis of data from the University of Colorado Hospital outpatient pharmacy system. The proportion of days covered (PDC) was calculated to measure adherence. Statistical analyses were performed to compare adherence rates between groups. RESULTS: The study included 865 PLWH, who filled 1,943 antiviral prescriptions with an average PDC of 84.5%. However, only 40% of patients had high enough adherence to achieve therapeutic benefits based on a criterion of at least 95% of scheduled doses taken. When separated by regimen, 282 patients filled single-tablet once-daily regimens; 295 patients filled multitablet once-daily regimens; and 288 patients filled multitablet twice-daily regimens. The calculated PDC of PLWH on a single-tablet once-daily regimen was 89.7% versus 81.0% for PLWH on a multitablet once-daily regimen (P less than 0.001). The average PDC for PLWH (n = 269) who filled 460 scheduled blood pressure prescriptions was 82.7%. The average PDC for PLWH (n = 295) filling 467 scheduled mental health prescriptions was 81.7%. This difference was statistically significant in adherence between ART and blood pressure medications of 2.5% (P = 0.013) and a difference between ART and scheduled mental health medications of 3.03% (P = 0.002). For the comparator group of similar patients without HIV, 895 patients filled 1,398 scheduled blood pressure medications, with an average adherence of 83.8%. The difference between groups was not statistically significant (P = 0.390). For scheduled mental health medications in the comparator group, there were 666 patients filling 828 prescriptions. The comparator group had a higher average PDC than PLWH, with 85.1% versus 81.7%, respectively (P = 0.009). CONCLUSIONS: Based on average PDC, PLWH filling prescriptions at the University of Colorado Hospital Infectious Disease Group Practice pharmacy had an adherence of 84.5% to ART. However, only 40% of patients were adherent at the needed 95% level for therapeutic effects. Additionally, PLWH were more adherent to single-tablet once-daily regimens than to multitablet once-daily regimens or multitablet twice-daily regimens. Adherence in PLWH to HIV ART was better than the same patients' adherence to scheduled blood pressure and scheduled mental health medications. Levels of adherence still need to be improved to optimal to reduce rates of resistance and maximize therapeutic durability of selected regimens. When analyzed with the comparator group, adherence in PLWH to scheduled blood pressure medications was similar, but adherence to scheduled mental health medications was slightly worse. Further work is needed to address nonadherence among PLWH, including their adherence both to ART and to medications prescribed for other chronic diseases.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Infecções por HIV/tratamento farmacológico , Adesão à Medicação , Psicotrópicos/uso terapêutico , Centros Médicos Acadêmicos , Humanos , Saúde Mental , Pessoa de Meia-Idade , Pacientes Ambulatoriais , Farmácia , Estudos RetrospectivosRESUMO
A 44-year-old white man presented to the emergency department with a 3-day history of priapism requiring a surgically performed distal penile shunt. A drug-drug interaction is the suspected cause whereby CYP3A4 inhibition by boceprevir led to increased exposures of doxazosin, tamsulosin, and/or quetiapine, resulting in additional α-adrenergic blockade.
Assuntos
Antagonistas Adrenérgicos alfa/efeitos adversos , Inibidores do Citocromo P-450 CYP3A , Interações Medicamentosas , Priapismo/diagnóstico , Priapismo/etiologia , Prolina/análogos & derivados , Receptores Adrenérgicos alfa/efeitos dos fármacos , Antagonistas Adrenérgicos alfa/administração & dosagem , Adulto , Citocromo P-450 CYP3A , Humanos , Masculino , Priapismo/cirurgia , Prolina/administração & dosagem , Prolina/efeitos adversosRESUMO
A reversed-phase high performance liquid chromatographic (LC), tandem mass spectrometry (MS/MS) assay for the determination of tenofovir (TFV) and emtricitabine (FTC) in dried blood spots (DBS) from human whole blood was developed and validated. Whole blood samples were spotted, dried, and a 3mm punch was extracted with methanol for analysis by LC-MS/MS utilizing stable isotope labeled internal standards. The assay was validated over the range of 2.5-1000ng/mL for TFV and 2.5-5000ng/mL for FTC. The method was accurate (within ±15% of control) and precise (coefficient of variation ≤15%) for hematocrit concentrations ranging from 25% to 76%; using edge punches vs. center punches; and spot volumes of 10-50µL. Analytes were stable for five freeze/thaw cycles and up to 6 days at room temperature, whereas long-term storage required -20°C or -80°C. Comparison of TFV and FTC in DBS vs. plasma yielded r(2)≥0.96, indicating that DBS can be used as a plasma alternative for pharmacokinetic analyses in vivo.
Assuntos
Adenina/análogos & derivados , Desoxicitidina/análogos & derivados , Organofosfonatos/análise , Organofosfonatos/sangue , Adenina/análise , Adenina/sangue , Calibragem , Cromatografia Líquida , Desoxicitidina/análise , Desoxicitidina/sangue , Teste em Amostras de Sangue Seco , Estabilidade de Medicamentos , Emtricitabina , Hematócrito , Humanos , Controle de Qualidade , Reprodutibilidade dos Testes , Espectrometria de Massas em Tandem , Temperatura , TenofovirRESUMO
Tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV) and hepatitis B, is renally eliminated and has been associated with renal toxicities. Dose adjustments are recommended for patients with creatinine clearance (CrCL) <50 mL/min. We retrospectively determined the frequency in which HIV clinic providers adjusted TDF doses in patients with CrCL <50 mL/min over a 2-year period and compared clinical outcomes in patients who had TDF dose adjustments based on CrCL <50 mL/min versus those who did not. Thirty-nine patients with CrCL <50 mL/min were identified. Dose-adjusted patients (N = 9) continued their TDF-based antiretroviral regimens for 21 months longer following the first CrCL < 50 mL/min (P = .0193) and had gains in CD4 cell counts over 12 months (P = .0009). There were no statistically significant differences in CrCL or percentage of patients with detectable HIV-1 RNA at 6 and 12 months following first CrCL <50 mL/min in those who did versus did not have a TDF dose adjustment. In summary, HIV providers often failed to dose-adjust TDF in patients with CrCL <50 mL/min, but dose-adjusted patients appeared to stay on their TDF-based regimens longer and have greater gains in CD4 cells. Larger, prospective studies are needed to validate these results.
Assuntos
Adenina/análogos & derivados , Fármacos Anti-HIV/efeitos adversos , Rim/efeitos dos fármacos , Ácidos Fosforosos/efeitos adversos , Adenina/administração & dosagem , Adenina/efeitos adversos , Adulto , Creatinina/sangue , Feminino , Humanos , Rim/fisiologia , Masculino , Pessoa de Meia-Idade , Ácidos Fosforosos/administração & dosagem , Estudos RetrospectivosRESUMO
Tenofovir (TFV) disoproxil fumarate (TDF)±emtricitabine (FTC) are widely used for HIV treatment and chemoprophylaxis, but variable adherence may lead to suboptimal responses. Methods that quantify adherence would allow for interventions to improve treatment and prevention outcomes. Our objective was to characterize the pharmacokinetics of TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs); to extend the RBC analysis to dried blood spots (DBSs); and to model how RBC/DBS monitoring could inform recent and cumulative drug exposure/adherence. Blood samples were collected from 17 HIV-negative adults at 5 visits over a 30-day pharmacokinetics study of daily oral TDF/FTC. Dosing was discontinued on day 30 and blood was collected on days 35, 45, and 60 during the washout period. Plasma/RBCs/PBMCs/DBSs were all quantified by liquid chromatography/tandem mass spectrometry. DBSs were paired with RBCs and plasma for comparisons. The median (interquartile range) RBC TFV-DP half-life was 17.1 (15.7-20.2) versus 4.2 (3.7-5.2) days in PBMCs. At steady state, TFV-DP was 130 fmol/10(6) RBCs versus 98 fmol/10(6) PBMCs. FTC-TP was not quantifiable in most RBC samples. TFV-DP in RBCs versus DBSs yielded an r(2)=0.83. TFV-DP in DBSs was stable at -20°C. Simulations of TFV-DP in RBCs/DBSs, when dosed from one to seven times per week, demonstrated that each dose per week resulted in an average change of approximately 19 fmol/10(6) RBCs and 230 fmol/punch. TFV and FTC in plasma versus DBSs was defined by y=1.4x; r(2)=0.96 and y=0.8x; r(2)=0.99, respectively. We conclude that DBSs offer a convenient measure of recent (TFV/FTC) and cumulative (TFV-DP in RBCs) drug exposure with potential application to adherence monitoring.